Veeda Lifesciences Partners with Mango Sciences to Revolutionize Clinical Trials with AI

Veeda Lifesciences, a leading global contract research organization (CRO), has announced a strategic partnership with Boston-based Mango Sciences to integrate artificial intelligence into its clinical trial services. The collaboration aims to enhance trial efficiency, patient diversity, and data quality across Veeda’s global operations, particularly in oncology drug development.

 

Key Highlights:

 

Veeda has made a strategic investment in Mango Sciences to leverage its proprietary AI platform, Querent™, for automating patient identification and improving trial design.

 

The AI integration will enable faster, more precise recruitment of globally representative patient cohorts, especially non-Caucasian populations, aligning with regulatory expectations for diversity.

 

The Querent™ platform incorporates Large Language Models (LLMs) and Generative AI to optimize real-world evidence, trial monitoring, and patient-drug matching.

 

This partnership supports Veeda’s broader digital transformation strategy, following its acquisition of Health Data Specialists (Heads) and expansion into Europe.

 

Strategic Significance:

 

The collaboration positions Veeda as one of the few CROs globally with AI-driven oncology trial capabilities.

 

It enhances operational efficiency by streamlining data management, reducing trial timelines, and lowering costs.

 

The move strengthens Veeda’s competitive edge in serving small and mid-sized biotech and pharma clients across 26 countries.

 

Outlook: With this AI-powered leap, Veeda is set to redefine clinical trial execution in emerging markets and beyond. The partnership with Mango Sciences not only accelerates innovation but also reinforces Veeda’s commitment to inclusive, tech-enabled drug development.

 

Sources: PR Newswire, Veeda Lifesciences, Mango Sciences, PharmaSalmanac.